Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry

Virology Journal

Volumn 10, Issue , 2013, Pages

  Wen, Zhiyuan ^a   Zhao, Bolin ^a   Song, Kun ^a   Hu, Xule ^a   Chen, Weiye ^a   Kong, Dongni ^a   Ge, Jinying ^a   Bu, Zhigao ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Ebola virus; Glycoprotein; Macropinocytosis; Recombinant Newcastle disease virus; Virus entry

Indexed keywords

TRYPSIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; EBOLA VIRUS; FEMALE; INTERNALIZATION; MEMBRANE FUSION; MOUSE; NEWCASTLE DISEASE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PINOCYTOSIS; POULTRY; RECEPTOR BINDING; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WEIGHT GAIN;

EBOLA VIRUS; MUS; NEWCASTLE DISEASE VIRUS;

ANIMALS; CELL LINE; CRICETINAE; ENDOCYTOSIS; MICE; NEWCASTLE DISEASE VIRUS; RECOMBINANT PROTEINS; REVERSE GENETICS; SURVIVAL ANALYSIS; VIRAL ENVELOPE PROTEINS; VIRULENCE; VIRUS INTERNALIZATION;

EID: 84887069189     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-331     Document Type: Article

References (73)

1. Ebola haemorrhagic fever. Feldmann H, Geisbert TW, Lancet 2011 377 849 862 10.1016/S0140-6736(10)60667-8 21084112
2. Ebola virus: unravelling pathogenesis to combat a deadly disease. Hoenen T, Groseth A, Falzarano D, Feldmann H, Trends Mol Med 2006 12 206 215 10.1016/j.molmed.2006.03.006 16616875 (Pubitemid 43728410)
3. Molecular biology and evolution of filoviruses. Feldmann H, Klenk HD, Sanchez A, Arch Virol Suppl 1993 7 81 100 10.1007/978-3-7091-9300-6-8 8219816
4. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. Chan SY, Speck RF, Ma MC, Goldsmith MA, J Virol 2000 74 4933 4937 10.1128/JVI.74.10.4933-4937.2000 10775638 (Pubitemid 30237927)
5. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. Ito H, Watanabe S, Sanchez A, Whitt MA, Kawaoka Y, J Virol 1999 73 8907 8912 10482652 (Pubitemid 29441763)
6. A system for functional analysis of Ebola virus glycoprotein. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y, Proc Natl Acad Sci USA 1997 94 14764 14769 10.1073/pnas.94.26.14764 9405687 (Pubitemid 28041448)
7. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. Wool-Lewis RJ, Bates P, J Virol 1998 72 3155 3160 9525641 (Pubitemid 28175558)
8. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ, Science 1998 279 1034 1037 10.1126/science.279.5353.1034 9461435 (Pubitemid 28113305)
9. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, Dolnik O, Klenk HD, Science 2001 291 1965 1969 10.1126/science.1057269 11239157 (Pubitemid 32216997)
10. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ, Nat Med 2000 6 886 889 10.1038/78645 10932225 (Pubitemid 30644746)
11. Ebola virus can be effectively neutralized by antibody produced in natural human infection. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, Peters CJ, Parren PW, Burton DR, J Virol 1999 73 6024 6030 10364354 (Pubitemid 29274889)
12. Epitopes involved in antibody-mediated protection from Ebola virus. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK, Science 2000 287 1664 1666 10.1126/science.287.5458.1664 10698744 (Pubitemid 30127770)
13. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, et al. PLoS Med 2006 3 177 10.1371/journal.pmed.0030177 16683867 (Pubitemid 43987829)
14. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, et al. Nat Med 2011 17 1128 1131 10.1038/nm.2447 21857654
15. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, et al. Nat Med 2005 11 786 790 10.1038/nm1258 15937495 (Pubitemid 41021212)
16. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H, Jones SM, PLoS One 2009 4 5547 10.1371/journal.pone.0005547 19440245
17. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A, Vaccine 2010 29 17 25 10.1016/j.vaccine.2010.10.024 21034822
18. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, et al. J Virol 2011 85 10605 10616 10.1128/JVI.00558-11 21849459
19. Alexander DJ, Newcastle Disease American Association for Avian Pathologists: Kennett Square, PA 1989
20. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. Peeters BP, de Leeuw OS, Koch G, Gielkens AL, J Virol 1999 73 5001 5009 10233962 (Pubitemid 29246761)
21. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Panda A, Huang Z, Elankumaran S, Rockemann DD, Samal SK, Microb Pathog 2004 36 1 10 10.1016/j.micpath.2003.07.003 14643634 (Pubitemid 37476184)
22. Newcastle disease virus antibodies in human sera. Charan S, Mahajan VM, Agarwal LP, Indian J Med Res 1981 73 303 307 7275226 (Pubitemid 11042180)
23. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C, Gene Ther 1999 6 63 73 10.1038/sj.gt.3300787 10341877 (Pubitemid 29043695)
24. The role of the amino terminus of F1 of the Newcastle disease virus fusion protein in cleavage and fusion. Morrison T, McQuain C, Sergel T, McGinnes L, Reitter J, Virology 1993 193 997 1000 10.1006/viro.1993.1214 8460504
25. Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Nagai Y, Klenk HD, Rott R, Virology 1976 72 494 508 10.1016/0042-6822(76)90178-1 948870
26. Alexander D, Newcastle Disease and Other Avian Paramyxoviridae Infections Ames: Iowa State University Press 1997
27. Generation and evaluation of a Newcastle disease virus-based H9 avian influenza live vaccine. Ge J, Tian G, Zeng X, Jiang Y, Chen H, Bua Z, Avian Dis 2010 54 294 296 10.1637/8731-032509-ResNote.1 20521648
28. Recombinant Newcastle disease virus as a vaccine vector. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, Villar E, Garcia-Sastre A, Palese P, J Virol 2001 75 11868 11873 10.1128/JVI.75.23.11868-11873.2001 11689668 (Pubitemid 33063278)
29. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A, Proc Natl Acad Sci USA 2007 104 9788 9793 10.1073/pnas.0703584104 17535926 (Pubitemid 47175345)
30. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy BR, Samal SK, Collins PL, J Virol 2005 79 13275 13284 10.1128/JVI.79.21.13275-13284.2005 16227250 (Pubitemid 41508142)
31. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, Bukreyev A, J Virol 2010 84 1489 1503 10.1128/JVI.01946-09 19923177
32. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, Wang X, Li Y, Hu S, Jiang Y, et al. J Virol 2007 81 150 158 10.1128/JVI.01514-06 17050610 (Pubitemid 44975155)
33. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK, J Virol 2011 85 10529 10541 10.1128/JVI.05050-11 21849467
34. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, Garcia-Sastre A, J Virol 2009 83 584 597 10.1128/JVI.01443-08 19004953
35. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. Ge J, Wang X, Tao L, Wen Z, Feng N, Yang S, Xia X, Yang C, Chen H, Bu Z, J Virol 2011 85 8241 8252 10.1128/JVI.00519-11 21632762
36. Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Kong D, Wen Z, Su H, Ge J, Chen W, Wang X, Wu C, Yang C, Chen H, Bu Z, Virology 2012 432 327 335 10.1016/j.virol.2012.06.001 22726244
37. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ, Vaccine 2010 28 4394 4401 10.1016/j.vaccine.2010.04.048 20434545
38. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, de Wit AA, Peeters BP, Moormann RJ, Vaccine 2010 28 2271 2276 10.1016/j.vaccine.2010.01.001 20079874
39. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Khattar SK, Collins PL, Samal SK, Vaccine 2010 28 3159 3170 10.1016/j.vaccine.2010.02.051 20189484
40. Newcastle disease virus as a vaccine vector for humans. Bukreyev A, Collins PL, Curr Opin Mol Ther 2008 10 46 55 18228181 (Pubitemid 351170594)
41. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, et al. J Clin Oncol 2002 20 2251 2266 10.1200/JCO.2002.08.042 11980996 (Pubitemid 34441652)
42. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmuller E, Buchcik R, Nagel M, Saeger HD, Clin Cancer Res 1996 2 21 28 9816085 (Pubitemid 26042174)
43. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke BH, Weidauer H, Schirrmacher V, Herold-Mende C, Cancer Res 2004 64 8057 8061 10.1158/0008-5472.CAN-04-1545 15520216 (Pubitemid 39446943)
44. OIE, Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2011 Paris: Office International des Epizooties 2011
45. Newcastle disease virus may enter cells by caveolae-mediated endocytosis. Cantin C, Holguera J, Ferreira L, Villar E, Munoz-Barroso I, J Gen Virol 2007 88 559 569 10.1099/vir.0.82150-0 17251575 (Pubitemid 46210896)
46. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y, PLoS Pathog 2010 6 1001121 10.1371/journal.ppat.1001121 20886108
47. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA, PLoS Pathog 2010 6 1001110 10.1371/journal.ppat.1001110 20862315
48. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. Aleksandrowicz P, Marzi A, Biedenkopf N, Beimforde N, Becker S, Hoenen T, Feldmann H, Schnittler HJ, J Infect Dis 2011 204 Suppl 3 957 S967 10.1093/infdis/jir326 21987776
49. Shaping cups into phagosomes and macropinosomes. Swanson JA, Nat Rev Mol Cell Biol 2008 9 639 649 10.1038/nrm2447 18612320
50. Defining macropinocytosis. Kerr MC, Teasdale RD, Traffic 2009 10 364 371 10.1111/j.1600-0854.2009.00878.x 19192253
51. Virus entry by macropinocytosis. Mercer J, Helenius A, Nat Cell Biol 2009 11 510 520 10.1038/ncb0509-510 19404330
52. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Rodal SK, Skretting G, Garred O, Vilhardt F, van Deurs B, Sandvig K, Mol Biol Cell 1999 10 961 974 10.1091/mbc.10.4.961 10198050 (Pubitemid 29193724)
53. Acute cholesterol depletion inhibits clathrin-coated pit budding. Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE, Proc Natl Acad Sci USA 1999 96 6775 6780 10.1073/pnas.96.12.6775 10359788 (Pubitemid 29274959)
54. Recombinant nipah virus vaccines protect pigs against challenge. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M, J Virol 2006 80 7929 7938 10.1128/JVI.00263-06 16873250 (Pubitemid 44182294)
55. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, et al. Proc Natl Acad Sci USA 2012 109 5797 5802 10.1073/pnas.1117208109 22454499
56. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, et al. Vaccine 2006 24 417 425 10.1016/j.vaccine.2005.08.041 16176847 (Pubitemid 41832544)
57. Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS. Vaccari M, Halwani R, Patterson LJ, Boasso A, Beal J, Tryniszewska E, Hryniewicz A, Venzon D, Haddad EK, El-Far M, et al. J Virol 2013 87 3526 3537 10.1128/JVI.02686-12 23325679
58. Newcastle disease virus V protein is a determinant of host range restriction. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P, J Virol 2003 77 9522 9532 10.1128/JVI.77.17.9522-9532.2003 12915566 (Pubitemid 37011047)
59. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF, J Virol 2003 77 1501 1511 10.1128/JVI.77.2.1501-1511.2003 12502864 (Pubitemid 36055570)
60. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. Huang Z, Krishnamurthy S, Panda A, Samal SK, J Virol 2003 77 8676 8685 10.1128/JVI.77.16.8676-8685.2003 12885886 (Pubitemid 36936078)
61. Interferon induction by Newcastle disease virus in mice. Blach-Olszewska Z, Arch Immunol Ther Exp (Warsz) 1970 18 418 441 5529491
62. Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid. Brehm G, Kirchner H, J Interferon Res 1986 6 21 28 10.1089/jir.1986.6.21 2422299 (Pubitemid 16004154)
63. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A, J Virol 2006 80 2267 2279 10.1128/JVI.80.5.2267-2279.2006 16474134 (Pubitemid 43271533)
64. Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan. Kunz S, Rojek JM, Perez M, Spiropoulou CF, Oldstone MB, J Virol 2005 79 5979 5987 10.1128/JVI.79.10.5979-5987.2005 15857984 (Pubitemid 40617204)
65. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Ogino M, Ebihara H, Lee BH, Araki K, Lundkvist A, Kawaoka Y, Yoshimatsu K, Arikawa J, Clin Diagn Lab Immunol 2003 10 154 160 12522053 (Pubitemid 36133843)
66. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. Kaku Y, Noguchi A, Marsh GA, McEachern JA, Okutani A, Hotta K, Bazartseren B, Fukushi S, Broder CC, Yamada A, et al. J Virol Methods 2009 160 7 13 10.1016/j.jviromet.2009.04.037 19433112
67. Efficacy of DNA immunization with F and G protein genes of Nipah virus. Wang X, Ge J, Hu S, Wang Q, Wen Z, Chen H, Bu Z, Ann N Y Acad Sci 2006 1081 243 245 10.1196/annals.1373.029 17135518 (Pubitemid 44968780)
68. Fields Virology Philadelphia: Lippincott-Williams & Wilkins, Lamb RA, Kolakofsky D, 3 2001
69. Virus-cell and cell-cell fusion. Hernandez LD, Hoffman LR, Wolfsberg TG, White JM, Annu Rev Cell Dev Biol 1996 12 627 661 10.1146/annurev.cellbio.12.1. 627 8970739 (Pubitemid 26422726)
70. Paramyxovirus fusion: a hypothesis for changes. Lamb RA, Virology 1993 197 1 11 10.1006/viro.1993.1561 8212546
71. Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. Quinn K, Brindley MA, Weller ML, Kaludov N, Kondratowicz A, Hunt CL, Sinn PL, McCray PB Jr, Stein CS, Davidson BL, et al. J Virol 2009 83 10176 10186 10.1128/JVI.00422-09 19625394
72. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, et al. Nature 2011 477 340 343 10.1038/nature10348 21866103
73. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, et al. Embo J 2012 31 1947 1960 10.1038/emboj.2012.53 22395071